China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

Instil Bio Inc. (NASDAQ:TIL) saw its stock jump 10% after the company announced that the U.S. Food and Drug Administration ...

IOVA's ASCO update reiterates the value of Amtagvi in melanoma, but upcoming data in lung cancer and endometrial cancer in H2 ...

近年来，抗体药物偶联物（ADC）已成为恶性肿瘤领域的研究热点，不断在肺癌的治疗中取得突破性进展。6 月 23 日，基于 TROPION-Lung05 研究和 TROPION-Lung01 研究积极结果，美国食品药品监督管理局（FDA）加速批准 ...

The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

CHEST guideline updates support minimally invasive resection and targeted therapy to enhance survival in Stage I–II NSCLC.

Panelists discuss how the MARIPOSA study findings demonstrated significant progression-free survival and overall survival ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80% of all lung ...